Our findings provide new insights into the regulatory mechanism between EZH2 and miRNAs in ovarian cancer and some evidence for the application of miRNA related agents and EZH2 inhibitors in ovarian cancer treatment. This evidence concerns the gene EZH2 and ovarian cancer.